SABCS 2020 Recap - Exciting New Studies!

Options
Bestbird
Bestbird Member Posts: 2,818
edited January 2021 in Stage IV/Metastatic Breast Cancer ONLY

As many are aware, the San Antonio Breast Cancer Symposium (SABCS) 2020 was held virtually this year. There were several presentations about promising treatments for people with MBC, which are presented in my conference recap.

Two of the most encouraging drugs are Tesetaxel, an oral version of intravenous chemotherapy taxanes for which a New Drug Application is expected to be submitted this year, and the oral immunotherapy drug Eganelisib that is being studied among TNBC MBC patients with promising results!

Information from the SABCS 2020 recap has been incorporated in a comprehensive paperback and eBook entitled, "The Insider's Guide to Metastatic Breast Cancer," which is also available as a complimentary .pdf. The Guide includes material about approved MBC therapies in the US, Canada, Europe and Australia, symptom and side effect mitigation, cutting-edge research, and more. If you like the way the SABCS information is presented and want to start the New Year armed with science-based MBC information, please visit https://www.insidersguidembc.com/

To access the SABCS 2020 recap, please visit: https://www.insidersguidembc.com/sabcs

Thank you, and happy New Year!

Anne

    · Share on FacebookShare on Twitter

    Comments

    • candy-678
      candy-678 Member Posts: 3,950
      edited January 2021

      Thank you. Downloaded updated version.

      · Share on FacebookShare on Twitter
    • Cure-ious
      Cure-ious Member Posts: 2,626
      edited January 2021

      Thanks Anne!! Very excited to learn about eganelisib looking like it may synergize with IO, and hope they move this to ER-positive disease- would like to have heard more on the SERDs, but surely there will be a lot of news next year...

      · Share on FacebookShare on Twitter
    • Bestbird
      Bestbird Member Posts: 2,818
      edited January 2021

      Cure-ious, I think we're 2 - 3 years out re: approval of oral SERDS, and - when they hit - multiple approvals will be granted within a relatively short timeframe in a similar manner to what we've seen with CDK4/6 inhibitors.

      I just read of the failure of an experimental immunotherapy drug in combination with chemo for hormone receptor positive patients. HER2+ and TNBC subtypes appear to be more vulnerable to immunotherapy-based combinations thus far, and the bulk of promising new therapies seem to be for HER2+ (including triple positive) patients.

      With appreciation for your continued research and information-sharing, and best wishes for the New Year.

      · Share on FacebookShare on Twitter
    • Moissy
      Moissy Member Posts: 550
      edited January 2021

      Anne - Thanks for your continued updates and for the updated Guide to MBC! I have referred to it many times through the years. Thank you!

      · Share on FacebookShare on Twitter
    • Bestbird
      Bestbird Member Posts: 2,818
      edited January 2021

      Moissy, you are very welcome! If you know of anyone else who might benefit from the information, please pass it along!

      With best wishes,

      Anne


      · Share on FacebookShare on Twitter
    • SandiBeach57
      SandiBeach57 Member Posts: 1,617
      edited January 2021

      Hi Anne, I have your book. Are the data from SABC 2020 separated out or mixed in with current research therapies?

      Is it better to download the PDF and make notes in my book?

      · Share on FacebookShare on Twitter
    • Bestbird
      Bestbird Member Posts: 2,818
      edited January 2021

      SandiBeach57, I'm happy to say the information from SABCS 2020 has been fully incorporated into the manuscript of the book (and the complimentary .pdf).

      Whether your book has the updates is a question of timing. If you purchased the book prior to the end of Dec., it will not have the updates, and anything purchased or downloaded after the end of Dec. will have the updates.

      Best wishes!

      · Share on FacebookShare on Twitter

    Categories